Blackstone have announced a new collaboration with Moderna through a development and commercialisation funding agreement where funds managed by Blackstone Life Sciences and will provide up to $750 million to fund Moderna’s influenza program.
Takeda and Biological E. Limited, an India-based vaccines and pharmaceutical company, have announced a strategic partnership to accelerate access to QDENGA (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003) multi-dose vials.
Latika Mahajan, Assistant Manager, Life Sciences at The Smart Cube explores the declining demand for Covid-19 vaccines and looks ahead to what's next for mRNA.
Scientific and technological innovation is accelerating the development of effective cancer vaccines, report Drs. Daina Vanags, Cori Gorman and Christian K. Schneider of Biopharma Excellence.
Bruno Speder, VP of regulatory affairs & consultancy services, hVIVO, discusses how Human Challenge Trials (HCT) can be used in the framework of expedited review programs as part of drug and vaccine development.
Dr. Jan Ehlers, chief executive officer at Secop GmbH, shares the trends and challenges in the cold chain industry and the rising demand for vaccine transport solutions.
Adam Clore, director of development & innovation at Integrated DNA Technologies, shares the achievements and objectives of mRNA vaccines; from the 1990s to the COVID-19 pandemic, and the hopes for the future.
Russell Green, director product growth for Drug Discovery and Synthetic Biology, Automata, describes three reasons why automation should become an integral part of the vaccine development process.
Dr. Nicholas Jones, partner and patent attorney at Withers & Rogers, discusses what the pharma industry can learn from its experiences of working collaboratively during the COVID-19 pandemic by establishing best practice and minimising risks.
Peter Jensen, CEO and Chairman, Normax delves into why it’s time for mRNA vaccine equality to be established across the globe, how mRNA vaccines can help drive down the cost of vaccines, and support the long-term battle against future pandemics.
Luc Gagnon, vice president of vaccine sciences at Nexelis, gives an insight into the increase in vaccine hesitancy and the role that pharmaceutical and R&D industries need to take to address the problem.
